Business Description
Outlook Therapeutics is a New Jersey-based company working to bring new treatments to patients with serious eye diseases. Its primary focus is ONS-5010, a specially formulated eye drug currently in late-stage clinical trials for wet age-related macular degeneration, a condition that can cause severe vision loss. The company works alongside Cencora to support its commercial efforts and has been operating under its current name since 2018, having originally been founded in 2010.
